Research Analysts Set Expectations for ZNTL Q3 Earnings

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) – Leerink Partnrs issued their Q3 2025 earnings per share (EPS) estimates for Zentalis Pharmaceuticals in a research note issued on Wednesday, February 5th. Leerink Partnrs analyst A. Berens anticipates that the company will earn ($0.41) per share for the quarter. The consensus estimate for Zentalis Pharmaceuticals’ current full-year earnings is ($2.42) per share. Leerink Partnrs also issued estimates for Zentalis Pharmaceuticals’ FY2025 earnings at ($2.00) EPS and FY2026 earnings at ($1.81) EPS.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.56) EPS for the quarter, topping the consensus estimate of ($0.92) by $0.36.

Several other analysts have also commented on the stock. Wells Fargo & Company decreased their price target on shares of Zentalis Pharmaceuticals from $8.00 to $6.00 and set an “equal weight” rating for the company in a research report on Thursday, January 30th. Wedbush reissued a “neutral” rating and set a $4.00 target price on shares of Zentalis Pharmaceuticals in a research report on Friday, January 24th. HC Wainwright cut their price target on shares of Zentalis Pharmaceuticals from $20.00 to $10.00 and set a “buy” rating on the stock in a report on Wednesday, January 29th. Guggenheim decreased their price objective on Zentalis Pharmaceuticals from $12.00 to $8.00 and set a “buy” rating for the company in a report on Friday, November 15th. Finally, UBS Group dropped their target price on Zentalis Pharmaceuticals from $5.00 to $2.20 and set a “neutral” rating on the stock in a research note on Tuesday, January 28th. Five research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $8.24.

Zentalis Pharmaceuticals Price Performance

Shares of ZNTL stock opened at $2.08 on Monday. The stock’s 50-day moving average is $2.72 and its 200 day moving average is $3.15. Zentalis Pharmaceuticals has a 1-year low of $1.61 and a 1-year high of $18.07. The company has a market cap of $148.22 million, a P/E ratio of -0.84 and a beta of 1.81.

Insider Buying and Selling at Zentalis Pharmaceuticals

In other Zentalis Pharmaceuticals news, Director Jan Skvarka acquired 60,000 shares of the firm’s stock in a transaction on Friday, January 31st. The stock was acquired at an average cost of $1.72 per share, for a total transaction of $103,200.00. Following the purchase, the director now owns 149,551 shares in the company, valued at approximately $257,227.72. The trade was a 67.00 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 3.60% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Primecap Management Co. CA boosted its holdings in Zentalis Pharmaceuticals by 1.5% in the fourth quarter. Primecap Management Co. CA now owns 1,520,630 shares of the company’s stock valued at $4,608,000 after purchasing an additional 22,600 shares during the last quarter. Verition Fund Management LLC boosted its stake in shares of Zentalis Pharmaceuticals by 172.1% in the third quarter. Verition Fund Management LLC now owns 1,504,320 shares of the company’s stock worth $5,536,000 after buying an additional 951,500 shares during the last quarter. GSA Capital Partners LLP boosted its stake in shares of Zentalis Pharmaceuticals by 138.5% in the third quarter. GSA Capital Partners LLP now owns 608,585 shares of the company’s stock worth $2,240,000 after buying an additional 353,384 shares during the last quarter. Charles Schwab Investment Management Inc. grew its holdings in Zentalis Pharmaceuticals by 22.4% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 497,362 shares of the company’s stock worth $1,507,000 after acquiring an additional 91,152 shares during the period. Finally, Connor Clark & Lunn Investment Management Ltd. raised its position in Zentalis Pharmaceuticals by 50.6% during the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 345,039 shares of the company’s stock valued at $1,045,000 after acquiring an additional 115,901 shares in the last quarter.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.